Press Releases

23andMe+ members can now gain insights on the chronic autoimmune condition SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune
May 9, 2023
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of
May 8, 2023
ESG report outlines strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations SOUTH SAN FRANCISCO, Calif. -- MARCH 29, 2023 -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics
March 29, 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the
March 14, 2023
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be
February 22, 2023
Displaying 11 - 20 of 22
Print Page
RSS Feeds
Email Alerts
Contact IR